AI assistant
Cellectis — Share Issue/Capital Change 2019
Jul 4, 2019
1190_dva_2019-07-04_75ef9380-07ac-483c-8000-cf82499255bc.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority)
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital |
Total number of voting rights |
|---|---|---|
| 06/30/2019 | 42,445,669 | 51,240,605 |
About Cellectis
Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 19 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.
For further information, please contact:
Media contacts:
Jennifer Moore, VP of Communications, 917-580-1088, [email protected] Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, [email protected]
IR contact: Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008, [email protected]